Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Apr 22, 2021 6:01pm
81 Views
Post# 33052403

RE:RE:RE:RE:RE:RE:How is this even possible in this market?

RE:RE:RE:RE:RE:RE:How is this even possible in this market?

This would be the culmination of more than two years work, they really need to give it the fanfare it deserves. Any other NASH company would have been building it's audience and telling the story for many years before starting the Ph3. The company needs to think about all that effort being condensed into one moment.

 


SPCEO1 wrote: I agree we should brace ourselves for a smallish reaction to the news that the FDA has agreed with TH on a phase III NASH protocol. The evidence that no one is paying attention or willing to give TH credit for this is pretty overwhelming. Maybe at that point, people who keep saying it is the need for the phase III to be legitimized by the FDA that is required for the stock to reflect it will realize it is a bigger problem. Yesterday, Paul basically told us it is effectively a done deal anyway and there has been no reaction to that. No oneis paying attention as the company ahs succeeded beyond my imagination on getting to phase III in general NASH and failed miserably on getting the market to care about that. Which is why it is so maddening! It is not like TH's leadership has screwed up at every turn, just the opposite. But they have really made a hash of how their stunning successes are viewed by the markets. These are unforced errors, own goals and they need to be cleaned up yesterday.
 

stockman75 wrote: FTV, do you really think confirmation of NASH moves anything? My guess is confirmation of the protocal doesn't even move the needle. I don't think anyone is paying attention to THTX except a very few. 

My guess. Only breakthrough cancer news starts to move this old horse....

Hope you are right though! 



FredTheVoice wrote: Said it before, and a couple of times in the last weeks....

No confirmation about NASH, no big mouvement around the stock.....

Nothing to do with management.....

FTV.

 




<< Previous
Bullboard Posts
Next >>